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1. Introduction  
Glaucoma remains one of the leading causes of acquired blindness worldwide (Thylefors & 
Negrel, 1994; Quigley & Broman, 2006). Open-angle glaucoma (OAG) including primary 
open-angle glaucoma (POAG), and normal-tension glaucoma (NTG), is the most common 
type of glaucoma and is just a representative chronic disease such as hyptertension and 
diabetes mellitus (Schwartz & Quigley, 2008; Quigley, 2011). Because the ultimate goal of 
glaucoma treatment is to maintain long-term visual function, glaucomatous patients require 
essentially lifelong follow-up. Thus, we need an approach to glaucoma management that 
considers patients’ present visual functions as well as their future prognosis.  
The pathogenesis of glaucomatous optic neuropathy as well as the details of its long-term 
progression have not beeen clered yet. Many clinical trials have confirmed the importance of 
intraocular pressure (IOP) in the development and progression of OAG (Kass et al., 2002; 
Gordon et al, 2002; Heijl et al. 2002; 2003; Leske et al, 1999; 2003; Collaborative normal-
tension glaucoma study group, 1998; 2001; Anderson et al, 2003; The AGIS Investigators, 
1994; 2000; Katz, 1999; Musch et al, 2009; Parrish et al, 2009; Chauhan et al, 2008). These 
studies have shown that lowering IOP reduces the risk of developing OAG and slows its 
progression. The aim of current glaucoma treatment approaches is to maintain patients’ 
visual function for as long as possible by reducing IOP. In addition to visual function, of 
course, we monitor patients’ IOP, optic discs, and retinal changes. Since preservation of 
visual fields is the final outcome in glaucoma management, ongoing evaluation of patients’ 
visual fields must be the most important activity in clinical practice. Recently, the 
morphological evaluation of optic disc cupping, retinal nerve fiber layer defects, and the 
retinal ganglion cell complex by imaging systems such as optical coherence tomography 
(OCT) has become popular (Wollstein et al, 2005; Tan O et al, 2009). After all these systems 
provide only the ability to reliably and safely detect or predict glaucoma progression beside 
monitering visual field and visual acuity (Hood & Kordon, 2007; Harwerth et al, 2010; 
Parrish et al, 2009).  
Standard automated perimetry (SAP) is used to examine and evaluate visual fields, but the 
technique is difficult to perform and have still has many problems. Furthermore, there is 
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currently no consensus on the proper method of evaluating visual field progression despite 
the fact that it is one of the most important aspects of glaucoma management. Spry and 
Johnson (2002) grouped procedures for detection of glaucomatous visual field defects into 
four categories: 1) subjective clinical judgment, 2) defect classification systems, 3) trend 
analyses, and 4) event analyses. Clinical judgment consists of the simple subjective 
observation of sequential visual field test results and is the oldest method of identifying 
visual field progression. Though it is, easy to perform, requires no additional instruments, 
and is useful in clinical practice, it is a subjective, inexact method and is not suitable for 
evaluating the details of long-standing glaucoma progression. Defect classification systems 
have often been used in major clinical trials for glaucoma, including the Advanced 
Intervention Glaucoma Study (AIGS) (The AGIS Investigators, 1994; 2000), and the 
Collaborative Initial Treatment Study (CIGTS) (Katz, 1999; Musch et al, 2009; Parrish et al, 
2009). These systems seem to be more reliable than the others at detecting progression 
(Mayama et al, 2004). However, each clinical trial set different progression criteria, and 
various individual criteria were suitable only for specific populations or disease stages (Heijl 
et al, 2008a). Event-type analysis (Hitchings 1994; Casas-Llera et al, 2009) and trend-type 
analysis (Holmin & Krakau, 1980; 1982; McNaught et al, 1995; Wild et al, 1989) have often 
been used in clinical practice since SAP instruments were introduced. Event-type analysis 
uses 2 or 3 visual field tests to establish a baseline, then compares subsequent tests to this 
baseline. Progression is considered to have taken place when definite sensitivity loss occurs, 
usually 2 or 3 dB from baseline. Cases with rapid progression can be picked up with this 
method earlier than with trend-type analysis. Because of variability in test results, however, 
the decision that a case has progressed is often reversed by subsequently improved results. 
A more common method of evaluating progression is trend-type analysis, which uses 
linear-regression analysis between multiple test results against time course. When the 
regression line has a significantly negative slope, we consider progression to have occurred. 
While trend-type analysis is more statistically reliable than event-type analysis, it requires 
longer follow-up periods and more test results. Some investigations have confirmed that 
trend-type analysis ideally requires 6 to 7 or more test results (Holmin & Krakau, 1982; Katz 
et al, 1997; Spry et al, 2000; Chauhan et al, 2008). Thus, for this type of analysis they 
recommended performing at least 3 visual field examinations within 2 to 3 years from the 
start of follow-up (Chauhan et al, 2008).  
Cases rarely progress rapidly; OAG in particular usually progresses slowly but predictably, 
generally requiring careful examinations for over 10 years (Collaborative normal-tension 
group study group, 2001). Two factors that are critical in monitoring the status of 
glaucomatous patients are ascertaining whether or not their visual field defects have 
progressed and the rate of progression (Johnson, 2010). It may be possible to predict the state 
of a patient’s visual fields as well as their quality of vision (QOV) if their condition continues 
to progress at a similar rate. Alternatively, we may evaluate the effects of additional 
treatments, medication changes, or glaucoma surgery by comparing progression rates between 
pre- and post-intervention. Although the time interval between the start of progression and its 
assessment during follow-up should depend on the speed of disease progression, defect 
classification systems and event-type analysis are only used to evaluate the extent of 
progression in the glaucomatous eyes. In this regard, trend-type analysis has a significant 
advantage relative to the other methods in terms of detecting visual field progression. 
Both event-type and trend-type analyses can be performed on whole visual fields or on 
individual test points. Mean deviation (MD) slope, derived the Humphrey Visual Field 
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Analyzer’s (HFA) Statpac 2, is a typical method used to perform trend-type analyses of 
entire visual fields. Glaucoma Progression Analysis (GPA) for HFA is one way of 
performing point-by-point event-type analysis. Modified methods of point-by-point event-
type analysis have been used to detect progression in the Collaborative Normal-Tension 
Glaucoma Study (CNTGS) (Collaborative normal-tension group study group, 1998; 2001; 
Anderson et al, 2003) and the Early Manifest Glaucoma Trial (EMGT) (Leske et al, 1999; 
2003; Heijl et al, 2002; 2003). Point-by-point trend-type analyses can be conducted using 
PROGRESSOR (Fitzke & Hitchings, 1996; Viswanathan et al, 1997), software package for 
Windows-based personal computers. Analysis of the entire visual field generally has high 
specificity but low sensitivity because changes in small, localized areas are averaged in with 
remaining stable areas (Heijl et al, 1986; 1987; Chauhan et al, 1990) . For example, the HFA 
30-2 program derives MD by averaging 76 test point values, meaning that this system 
evaluates 76 points equally. In contrast, point-by-point methods generally have high 
sensitivity but low specificity (O’Brien & Schwartz, 1990; Smith et al, 1996). There is no 
consensus on how to use the results of these tests in clinical practice, particularly if we 
detect progression in only few test points. We may have to establish criteria that enable us to 
identify an exact progression using point-by-point analysis. Many investigators have 
recommended cluster- or sector-based visual field analyses as methods that are intermediate 
between whole visual field and point-by-point approaches (Katz et al, 1997; Nouri-Mahdavi 
et al, 1997; Mayama et al, 2004). These may be more sensitive than whole visual field 
techniques and more specific than those using point-by-point assessment. Each OAG patient 
presents with a different patterns of progression and visual field defects. In addition, each 
visual field area may contribute differently to patients’ QOV (Sawada et al, 2010). In general, 
lower visual field problems cause greater subjective difficulty than trouble with the upper 
field. In addition, the central visual field is likely more important than peripheral fields 
(Gutierrez P et al, 1997; Parrish et al, 1997; McKean-Cowdin et al, 2007; Sumi et al, 2003; 
Sawada et al, 2011). It may prove beneficial to be able to use clusterization or sectorization to 
identify not just specific points but also areas of the visual field.  
In this study, we used HFA to perform a cluster-based trend-type analysis of OAG patients 
with long-term follow-up of up to 20 years. We evaluated the usefulness and reliability of 
this method in detecting progression of visual field defects. We also used this method to 
evaluate the patterns of longstanding OAG disease progression.  
2. Patients and methods 
2.1 Patient selection 
One eye each from 328 OAG patients were evaluated in this study based on the inclusion 
and exclusion criteria listed below. If a patient’s left and right eyes fit the criteria, we 
selected one eye randomly. All patients were examined and followed up at the Glaucoma 
Clinic in the Niigata University Medical and Dental Hospital. All patients were Japanese 
with similar social backgrounds and resided in the same urban area. The study was 
conducted in accordance with the Declaration of Helsinki and subsequent revisions thereof 
under approval of Niigata University. 
1. Inclusion criteria 
• Diagnosis of POAG or NTG by slit-lamp examination, of the optic disc and visual field, 
with normal anterior chamber angle, based on the Guidelines for Glaucoma from the 
European Glaucoma Society (2008) and Japan Glaucoma Society (2002).   
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• Age between 20 and 80 years at initial examination. 
• Follow-up data for at least 5 years with at least 7 reliable analyses (fixation losses, pseudo 
positive and negative below 30%) with a Humphrey Field Analyzer (HFA, Carl Zeiss 
Meditec Inc., Dublin, CA) using the Full-Threshold 30-2 program after exclusion of the 
first 2 or 3 visual field results to minimize learning effects. This was because our 
preliminary study and previous reports (Holmin, 1982; Katz, 1997; Spry, 2000; Chauhan, 
2008) showed that at least 5 or 6 sets of examination test results were necessary for exact 
trend-type analysis. No reliable, unexpected, or unreasonable results were excluded. 
• Reproducible glaucomatous visual field defects based on Anderson and Patella’s criteria 
(Anderson & Patella, 1999) in at least one eye at both the initial and last examinations. 
We focused only on whether visual field defect progression was detected in each eye or not. 
Thus, this study did not take into account patients’ medications, surgeries, or IOP during 
follow-up. However, we excluded eyes that demonstrated loss of visual function within the 
study period, for instance due to cataract progression, hypotony maculopathy, or bullous 
keratopathy. Cataract surgery was permitted, but if the visual field changed remarkably 
before or after surgery, the patient was excluded from the study.  
2. Exclusion criteria 
• Refractive errors (spherical equivalent powers less than −6D or more than +6D). 
• Corrected visual acuity under 20/40. 
• A significant cataract that could possibly influence visual acuity and visual field. Eyes 
with reductions of 3 or more steps in corrected visual acuity due to cataract progression 
were also excluded.  
• Overlap with other types of glaucoma, such as primary angle-closure glaucoma, 
pseudoexfoliation glaucoma, and steroid-induced glaucoma, even if there was only the 
possibility of overlap. We also excluded cases with shallow anterior chambers under 
grade 2 based on van Herick’s or Shaffer’s classifications.  
• Combinations of congenital optic disc anomalies (tilted disc syndrome, optic nerve 
hypoplasia, optic disc pits, or coloboma) or retinal diseases (diabetic retinopathy, retinal 
vein or artery occlusion, acquired macular degeneration, central serous 
chorioretinopathy, etc.). 
• Possibility of other optic nerve diseases (optic neuritis, anterior ischemic optic 
neuropathy, etc.) 
• Intracranial legions or trauma, possibly associated with visual field defects. 
2.2 Study visits 
Patients were observed approximately every 3 months. Study visits included IOP 
measurements with the Goldmann Applanation Tonometer. Perimetry was performed with 
an HFA using the Full-Threshold 30-2 program at least once a year. Patients also underwent 
best-corrected visual acuity measurements and standard eye examinations, including slit-
lamp and ophthalmoscopic examinations.  
2.3 Analysis of visual fields 
The central 30 degrees of patients’ visual fields were evaluated for defects using the mean 
deviation slope (MDS) of the HFA. In this study, the MDS is referred to as “the total MDS”. 
The 76 test points of the HFA central 30-2 full-threshold program were classified into upper 
and lower visual fields and into 10 visual field clusters (Fig. 1). Clusterization in this study 
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was based on Suzuki’s sectorization (Suzuki et al, 1993; 2001). Originally Suzuki et al. used 
mathematical calculations to divide the entire central 30-degree field into 15 sectors. We 
adapted original clusters in central 1 and 9, paracentral 2 and 10, and nasal 3 and 12. In 
addition to upper clusters, lower and temporal clusters were set by collecting 1 to 3 original 
sectors. We then calculated the average of total deviations in each cluster and performed a 
linear regression analysis using a Windows-based PC program, HfaFiles ver.5 (Beeline 
Co., Tokyo, Japan, URL; http://www.beline.co.jp). In this study, the MDS in upper or lower 
visual fields was called the hemi-MDS. In addition, the MDS in each cluster was designated 
as the clustered MDS. If the eyes showed a statistically significant negative correlation with 
time progress, visual field progression was defined as having occurred. When eyes had a 
negative total MDS value (<0 dB/yr) and a p-value <0.05, they were considered to have 
statistically significant progression of the whole visual field. Similarly, significant 
progression in either upper or lower field was identified as progression in the hemi-MDS. 
Furthermore, we considered clustered MDS progression to have occurred if significant 
progression was observed in at least 1 of the 10 clusters.  
 
 
 
 
Fig. 1. Setting of the 76 test points of the HFA central 30-2 full-threshold program for 3 types 
of trend-type analysis, the total MDS, the hemi-MDS and the clustered MDS. 
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The progression probabilities as determined by hemi and clustered MDS were compared 
with that of the total MDS. Additionally, hemi-MDS, clustered MDS, and the total MDS 
were compared in terms of progression rate and severity of the visual field defect. 
Progression rate was graded by the total MDS and severity was determined based on MD at 
the initial follow-up.  
2.4 Statistical analysis 
The MacNemar test was used to compare the total MDS and the hemi- or the clustered MDS. 
The MacNemar test was also used to compare upper and lower MDS and the MDS of each 
cluster in the clustered MDS.  
3. Results 
3.1 Patients profiles 
Subject characteristics are shown in Table 1. Subjects were 56.3 ± 11.3 (25−78) years old 
(average ± standard deviation, range) and had a mean initial MD of −7.69 ± 6.79 (+2.13 to 
−29.50) dB. They were followed up for 11.6 ± 4.09 (5−22) years. The mean number of valid 
examinations was 13.2 ± 6.05 (7−52). 
 
OAG 
Cases 328 eyes from 328 subjects 
gender (male / female) 162/166 
right / left eyes 173/155 
age at initial examination 56.2 ± 11.8 (25−78) yr-old 
mean deviation at initial examination −7.69 ± 6.79 (+2.13 to −29.50) dB 
follow-up duration 11.6 ± 4.1 (5−22) years 
number of visual field examinations 13.2 ± 6.1 (7−52) times 
Table 1. Patient profiles used in this study 
3.2 An example of 3 types of trend-type analyses 
An example of trend-type analyses based on the entire 30-degree field, upper or lower 
hemifield, and 10 clustered fields are shown in Fig. 2. The subject was 56-yr-old male with 
NTG and a baseline IOP of 19 mmHg, followed up for 9 years. In his right eye, while the 
total MDS was −0.20 dB/yr, the upper and lower MDS were -0.23 dB/yr and −0.19 dB/yr, 
respectively. In this case, 3 MDS indexes, the total, upper and lower MDS, were not 
statistically significant, so neither the total MDS nor hemi-MDS could be used to determine 
whether visual field progression had occurred. However, the clustered MDS in area 1 was 
−1.12 dB/yr (p = 4.17%), that in area 11 was −0.88 dB/yr (p = 0.07%) and that in area 7 and 8 
was −0.81 dB/yr (p = 0.14%). His right visual field had deteriorated locally and was 
evaluated as showing statistically significant progressive loss based only on the clustered 
MDS.  
3.3 Overall results 
All 328 eyes were analyzed in the same manner. Progression was seen in 228 eyes (69.3%) 
based on total MDS, 242 eyes (73.6%) based on hemi-MDS, and 303 (92.1%) eyes based on 
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Fig. 2. An example of 3 types of trend-type analysis that were performed in a patient with 
NTG 
clustered MDS (Table 2). Upper and lower MDS were quite similar in terms of their ability 
to detect progression (185 eyes, 56.2% by upper MDS and 178 eyes, 54.1% by lower MDS). 
Table 2 also lists the number of eyes showing progression as determined by clustered MDS. 
Overall, the probability of visual field defect progression was highest in clusters 2 and 10, 
and then in clusters 4, 5, and 6. Conversely, progression was seen least frequently in cluster 
15, then cluster 9. When comparing the same clusters of the upper and lower fields, the 
difference between clusters 1 and 9 was significant statistically by the McNemer test (p = 
0.0003). Similarly, the p-values for comparison of different cluster sets were 0.211 for clusters 
2 and 10, 1.000 for 3 and 11, 0.238 for 4, 5, and 6 compared to 12, 13, and 14, and 0.000 for 7 
and 8 compared to 15. 
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OAG (n = 328) 
# of eyes showing 
progression 
P 
total MDS 228 (69.3%) 
hemi-MDS 242 (73.6%) 0.014 
upper 185 (56.2%) 0.589 / lower 
lower 178 (54.1%) 
clustered MDS 303 (92.1%) 0.000 
 cluster 1 128 (38.9%) 0.006 / cluster 9 
cluster 2 149 (45.3%) 0.211 / cluster 10 
cluster 3 134 (40.7%) 1.000 / cluster 11 
clusters 4, 5, & 6 142 (43.2%) 0.238 / clusters 12, 13, & 14 
clusters 7 & 8 111 (33.7%) 0.000 / cluster 15 
cluster 9 96 (29.2%) 
cluster 10 165 (50.2%) 
cluster 11 134 (40.7%) 
clusters 12, 13, & 14 127 (38.6%) 
cluster 15 76 (23.1%)   
Table 2. Incidence of progression determined by 3 types of trend analysesθMDS: mean 
deviation slopeχ 
3.4 Results by disease severity or progression rate 
The number of eyes showing progression, as determined by the total, hemi- and clustered 
MDS, are shown categorized by MD stages (Table 3) and by total MDS (Table 4). The MD 
indicates the severity of visual field defects and the disease stage of OAG, and the total MDS 
marks the speed of progression in OAG. The number of eyes identified as showing 
progression was statistically similar between the total and hemi-MDS based on the 
McNemer test. Clustered MDS identified many more eyes exhibiting progression than the 
total or hemi-MDS in all eyes except for the eyes  
 
initial MD (dB) eyes
by total 
MDS 
by hemi 
MDS 
p 
By clustered 
MDS 
p 
MD ≧ 0 dB 28 25 (89.3%) 24 (85.7%) 1.000 26 (92.2%) 1.000 
0 > MD ≧ −2.5 dB 59 47 (79.7%) 49 (83.1%) 0.625 58 (98.3%) 0.001 
−2.5 > MD ≧ −5.0 dB 61 41 (67.2%) 41 (67.2%) 1.000 55 (90.2%) 0.000 
−5.0 > MD ≧ −7.5 dB 44 29 (65.9%) 34 (77.3%) 0.125 43 (97.7%) 0.000 
−7.5 > MD ≧ −10.0 dB 31 26 (83.5%) 28 (90.3%) 0.500 29 (93.5%) 0.250 
−10.0 > MD ≧ −15.0 dB 55 34 (61.8%) 36 (65.5%) 0.687 50 (90.9%) 0.000 
−15.0 > MD ≧ −20.0 dB 28 17 (60.7%) 20 (71.4%) 0.250 25 (89.3%) 0.008 
MD > −20.0 dB 22 9 (40.9%) 10 (45.5%) 1.000 17 (77.3%) 0.008 
Table 3. Incidence of progression determined by 3 types of trend analysis; Categorization by 
initial MD as the severity of visual field defect at the start of follow-up 
One of the main purposes of this report was to verify the advantages of cluster-based 
analysis in detecting progression and understanding glaucomatous visual fields. First, we 
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analyzed progression rates obtained by evaluating 30-degree whole fields (Table 3). In eyes 
with rapid progression under −0.7 dB/year of the total MD slope, all 3 methods showed a 
similar ability to identify progression of visual field defects in OAG. Clustered trend-type 
analysis was more effective in eyes with slower progression, particularly over −0.2 dB/year.  
 
total MDS (dB/yr) eyes
by total 
MDS 
by hemi 
MDS 
p 
by clustered 
MDS 
p 
MDS ≧ 0 dB/yr 22 0 (0%) 0 (0%) - 7 (31.8%) 0.016 
0 > MDS ≧ -0.1 dB/yr 29 1 (3.4%) 1 (3.4%) 1.000 22 (78.9%) 0.000 
−0.1 > MDS ≧ −0.2 dB/yr 45 23 (51.1%) 27 (60.0%) 0.289 42 (93.3%) 0.000 
−0.2 > MDS ≧ −0.3 dB/yr 50 36 (72.0%) 42 (84.0%) 0.109 50 (100%) 0.000 
−0.3 > MDS ≧ −0.5 dB/yr 79 73 (92.4%) 73 (92.4%) 1.000 79 (100%) 0.031 
−0.5 > MDS ≧ −0.7 dB/yr 44 40 (90.9%) 40 (90.9%) 0.125 44 (100%) 0.008 
−0.7 > MDS ≧ −1.0 dB/yr 36 36 (100%) 36 (100%) 1.000 36 (100%) 1.0000 
MDS > −1.0 dB/yr 23 23 (100%) 23 (100%) 1.000 23 (100%) 1.0000 
Table 4. Incidence of progression determined by 3 types of trend analysis; Categorization by 
total MDS (indicating progression rate of visual field defects) 
We also classified disease severity by initial total MD and then compared the 3 methods 
(Table 4). For all visual field stages except for eyes with initial MD over 0 dB and between 
−7.5 and −10.0 dB, clustered analysis was superior to total and hemifield analysis at 
detecting progression. It is generally difficult to identify progression of visual field defects 
in severely affected eyes (MD < −20 dB) using total MD slope due to appearance of a “floor 
effect.”  From the results, probability of progression decreased even with clustered analysis, 
but it picked up 17 from 22 eyes (77.3%) as progression. Clustered analysis may be able to 
evaluate progression using each residual visual field area even in these severe cases. 
3.5 Comparison among the 4 groups classified by total and clustered MDS 
The final step in our analysis was to separate the eyes into 4 groups based on prevalence of 
progression as determined by total and clustered MDS (Table 5). All 228 eyes identified as 
showing progression by total MDS were also detected by clustered MDS. Thus, we 
compared 3 groups with each other (Table 5). Twenty-five eyes without any progression 
tended to have shorter follow-up terms, fewer test times, more severe initial MD, and 
greater total MDS than those with statistically exact progression as determined both by total 
and clustered MDS. 
4. Discussion 
The main purposes of visual field testing are threefold: 1) to detect early sensitivity deficits, 
2) to aid differential diagnosis by identifying spatial patterns characteristic of sensitivity 
loss, and 3) to monitor patterns for evidence of progression, stability, or improvement of 
visual field deficits (Spry & Johnson, 2002). More than two decades have passed since SAP 
was introduced into clinical practice to manage and monitor glaucoma. Numerous clinical 
data from glaucomatous patients have been accumulated using this technique. The longer 
the follow-up period, the more we are able to understand about both the pathogenesis and 
disease course of OAG. The purpose of this study was to verify the usefulness and necessity 
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Progression by total MDS 
Yes No 
Progression by clustered MDS 
Yes No Yes No 
n= 228 0 75 25 
initial age 56.8±11.1 - 55.3±11.6 54.2±11.0 
p - 0.3261 0.2739 
follow-up duration 12.3±4.2 - 10.2±3.5 10.5±3.8 
p - 0.0001 0.0349 
test times 13.8±5.9 - 12.4±7.0 10.6±2.8 
p - 0.1154 0.0000 
initial MD −6.72±6.22 - −9.42±7.27 −11.30±8.30 
p - 0.0047 0.0124 
total MDS −0.54±0.34 - −0.18±0.19 0.03±0.12 
p - 0.0000 0.0000 
Table 5. Four groups’ classification by incidence of progression as determined by total MDS 
and clustered MDS.  
of cluster-based trend-type analysis in identifying progression of visual field defects in 
glaucomatous patients, and to use this method to elucidate the long-term disease course or 
manners of OAG. Numerous studies have shown that clusterization or sectorization is 
recommended because of their usefulness in evaluating individual test results as well as 
disease progression (Katz et al, 1997; Nouri-Mahdavi et al, 1997; Mayama et al, 2004). 
Furthermore, analysis of clinical data from patients followed up for as many as 20 years 
demonstrates other advantages: 1) cluster-based analysis is particularly useful for detecting 
local and minimal changes in glaucomatous visual fields, 2) detecting defects anywhere in 
the visual field is necessary for maintaining lifelong QOV in OAG, and 3) understanding 
OAG disease progression requires evaluation of both whole and local visual fields.  
This study used HfaFiles ver.5 (Beeline Co., Tokyo, Japan), a Windows-based PC program. 
Similar programs are available for managing and analyzing SAP results for clinical and 
research use. They generally tend to be easy to use and enough to manage for glaucomatous 
patients. HfaFiles ver.5 can store numerous HFA test results; in our clinic it maintains 
complete test results from the beginning of our use of HFA in 1988. It can also calculate 
various visual field parameters such as MD slope and staging data, as well as grading scores 
such as those from the AGIS and CIGTS. This program is useful both in the clinic and the 
laboratory. Standard settings allow calculation of the MD slope of the whole visual field as 
well as the total deviation (TD) slopes of the upper and lower hemifields. In addition, it has 
a function for calculating mean total deviations and their time trends after separating test 
points into clusters or sectors (Fig. 3). We used this function to perform trend-type analysis 
of the whole visual field, upper or lower hemifields, and 10 clustered visual fields, and then 
compared them with each other (Fig. 1).  
At first, we have to give a name for definition of the cluster setting. After we select the 
symbol, it should be placed on the HFA test points of each cluster we want to set. 
Clusterization in this study was based on Suzuki’s sectorization method described (1993; 
2001) in the Patients and Methods section. Various such approaches have been used for 
cluster or sector classification even with HFA (Wirtshafter et al, 1982; Sommer et al, 1987;  
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Fig. 3. Setting of the clusters using HfaFiles ver.5 (Beeline Co. Lit., Tokyo, Japan, URL; 
http://www.beline.co.jp ) 
Werner et al, 1989; Weber & Ulrich, 1991; Asman & Heijl, 1992; Mandava et al, 1993). 
Sommer et al. (1987) introduced a method that divided both upper and lower 30-degree 
hemifields into 5 sectors, then compared mirror image sectors to each other to evaluate HFA 
test results. The Glaucoma Hemifield Test (GHT) is a standard component of the HFA. GHT 
uses a different sector classification method but it is similar to that of Sommer et al. (1987). 
Incidentally, the Octopus Field Analyzer (OFA), another SAP, has a program, “Cluster 
Trend,” for clustered trend-type analysis using standard equipment.  
In this study, almost 90% of OAG eyes were classified as showing progression by clustered 
trend-type analysis after a mean follow-up duration of 11.6 years. This progression 
percentage was significantly higher than those determined by hemi or total visual fields 
analysis. The difference between the hemi and total visual field results was statistically 
significant, but barely so. It is possible that visual field defects in OAG progress very slowly 
and thus require longer-term follow-up, i.e., over 20 to 30 years. Progression of visual field 
defect must be more common than that we recognized. Managing OAG over the long-term 
will thus require us to pay significant attention to affected visual field areas and rate of 
progression. Mayama et al. (2004) set their original criterion as progression of glaucomatous 
visual field defects. They then compared the sensitivity and specificity of the methods using 
trend analysis of TD, MD, mean TD of a sectored visual field, and the original scoring used 
in the AIGS. They concluded that most of the methods using the TD slope were 
characterized by high sensitivity, the AIGS method had a very high specificity, and 
techniques using visual field sectors had reasonable sensitivity and specificity. Similarly, 
Nouri−Mahdavi et al. (1993) reported that fixed-effects multiple regression analysis of panel 
data using Octopus field analysis is an appropriate method for evaluating with experienced 
observers and pointwise univariate regression analysis. Clustered trend-type analysis is an 
important method for detecting and assessing the rate of progression in each visual field 
area. Its use in evaluating glaucoma patients is strongly recommended for those in clinical 
practice.  
The probability of progression and difference among clusters are interesting (Table 2). These 
findings should further our understanding of progression and its patterns in OAG. In 
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agreement with existing literature, the temporal visual fields showed a low probability of 
progression. When we compared the upper and lower fields, progression in the paracentral 
field, cluster 9, was lower than that in cluster 1. In addition, the arcuate (clusters 2 and 10) 
and nasal (clusters 3 and 11) fields had high incidences of progression that were similar in 
upper and lower fields. One common feature of glaucoma is that visual acuity is often 
protected. Morphologically, the macula is situated slightly below horizontal line of the optic 
disc. Possibly the majority of nerve fibers in cluster 9 arise from the macular bundles.    
Our goal in glaucoma management and treatment is the lifelong maintenance of patients’ 
visual function. When we consider the visual field by clusters, as presented in this study, 
each cluster may have different functions and may work together. For instance, cluster 10 
was related primarily to quality of vision (QOV), as were clusters 12, 13, and 14, to a lesser 
extent. The upper visual field in the better eye is likely to be important for driving. The 
details of the results will report in near future. Clustered or sectored evaluation of 
glaucomatous visual field defects and their progression can be used to formulate a 
management plan for each OAG patient. It is important to consider patients’ quality of life 
(QOL) and QOV both in the present and in the future. For example, cluster 10, the most 
important area for QOL, is disturbed less frequently than other areas, but nonetheless 
almost 30% of patients experience progression in this area. Although we have yet to confirm 
how each area of the visual field responds to glaucoma treatment, particularly IOP 
reduction, we can hopefully improve OAG patients’ QOL by using clustered evaluation 
such as that employed in this study. 
A possible clinical use of clustered trend-type analysis is shown in Fig. 4. and Table 6. She 
was a 63 yr-old female with NTG followed-up for 9 years. Her left eye showed a remarkable 
progression to be detected by all 3 trend-type analyses. By clustered analysis, the 
paracentral clusters 1 and 9, upper nasal cluster 3, and lower peripheral cluster 12, 13 and 14 
were indicated as progression. In addition, the progression rate in clusters 1, 9 and 3 was 
remarkable, under -1.0 dB/yr. The cluster 9, and cluster 12, 13 and 14, more likely relate 
with subjective disability from our previous study (Sawada et al., 2010). As our expectation,  
 
 
 
 
Fig. 4. and Table 6. A possible clinical use of clustered trend-type analysis. 
MDS 
(dB/year) 
P 
total MDS -0.53 ± 0.30 0.0033 
hemi-MDS       upper -0.39 ± 0.30 0.0172 
lower -0.54 ± 0.39 0.0123 
clustered MDS cluster 1 -1.71 ± 0.58 0.0001 
               cluster 2 +0.27 ± 0.44  
cluster 3 --1.29 ± 1.15 0.0323 
clusters 4, 5, & 6 -0.37 ± 0.40  
clusters 7 & 8 -0.18 ± 0.44  
cluster 9 -1.14 ± 0.83 0.0133 
cluster 10 -1.07 ± 0.74  
cluster 11 +0.01 ± 0.12  
clusters 12, 13, & 14 -0.31 ± 0.27 0.0278 
cluster 15 -0.12 ± 0.27  
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she complained gradual visual disturbance, particularly around the fixation point. We 
understood that her left eye needed more aggressive managements to maintain her 
QOL/QOV. We recommended MMC trabeculectomy for further reduction of IOP after that. 
Of course, this study has its limitations. This is a retrospective study, and such does not 
include clinical information such as IOP and glaucoma treatment interventions. In addition, 
this study cannot be used to clarify the natural history of OAG. For example, all 3 methods 
had difficulty detecting progression in cases with under −20 dB . In severe cases we have to 
consider both reduced sensitivities of our detection methods and the effects of aggressive 
glaucoma treatments. One of our previous studies showed that follow-up IOPs of Japanese 
OAG patients were reduced by about 8 to 9% after prostaglandin analogs became available. 
In this study, many patients had been followed since around 1990. Reduced follow-up IOPs 
may influence the incidence of progression as well as the areas of progression detected. The 
optimal methods for identifying progression of visual field defects in OAG have not yet 
been determined, nor have appropriate progression criteria. Thus, this study could compare 
the sensitivity but not the specificity of 3 methods of trend-type analysis. Mayama et al. 
(2004) established their own original criteria for progression and then compared several 
different methods, including MD slope from the whole field, sectored trend-type analysis, 
and defect classification systems. They concluded that the sectored trend-type analysis was 
the most reliable in terms of both sensitivity and specificity. Otherwise AIGS score had low 
sensitivity but high specificity for instance.  
A further task is to establish precisely how to use these types of detection methods in 
clinical practice. How should we interpret the detection of slight progression in only one 
temporal cluster?  This could hold significance in severe cases in which the temporal areas 
remained relatively unaffected. If this finding were seen in less advanced cases, we might 
consider it to be insignificant or perhaps an artifact. As mentioned above, cluster-based 
analysis is likely to be appropriate as an intermediate method between whole field analysis 
and that of individual test point. While it is evident that the clustered method is more 
sensitive than that using the whole field, its specificity might be reduced. We may have to 
set a significance level of 0.01 rather than 0.05 (Smith et al, 1996). Because this progression 
detection system with the clustered MDS uses 10 different clusters, the multiplicity possibly 
becomes a statistical issue to calculate an exact incidence or probability of progression. We 
might have to set 0.025 for the hemi-MDS and 0.005 for the clustered MDS instead of 0.05 as 
a significant level by a more strict statistical method like the Bonferroni method. Otherwise 
some investigators emphasize that setting of additional criteria is recommended, for 
example the progressive rate in each cluster, to determine whether progression is clinically 
significant (Noureddin et al, 1991; Birch et al, 1995). Fundamentally clusterization of the 
fields and the number of test points in each cluster may be critical for methodological 
accuracy.  
When we examine patients’ visual fields using these kinds of methods, we often find the 
clusters showing both impairment and improvement of MD in the same patient. This 
phenomenon is a reason to reduce the sensitivity of methods using the whole field. 
Although we have not yet identified the pattern and mechanism of recovery of visual field 
sensitivity, they possibly relate to neuroprotective effects or activation of the nervous system 
by glaucoma treatments.  
Recent glaucoma research has focused on the correlation between structure and function 
(Wollstein et al, 2005; Hood & Kordon, 2007; Tan O et al, 2009; Parrish et al, 2009; Harwerth 
www.intechopen.com
 
Glaucoma – Current Clinical and Research Aspects 
 
122 
et al, 2010) . One reason for this is that OCT has become widely available even in clinical 
practice. When we separate the peripapillary retinal nerve fiber layer into the several 
sectors, each has a corresponding cluster in the visual field. Cluster-based correlation should 
be more significant than that between the whole field and retinal nerve fiber layers (Hood & 
Kordon 2007). Cluster-based observations should be effective both from structural and 
functional points of view at predicting the progression and prognosis of OAG patients in the 
future. Future investigations should focus not only on the progression incidence in each 
cluster but also on the progression rate, as well as on the differences between high-tension 
glaucoma (HTG) and NTG. In addition, we should analyze the relation with glaucoma 
treatments. Perhaps the paracentral, arcuate, nasal, and upper or lower peripheral visual 
fields react differently to IOP reduction. 
5. Conclusion  
Clustered trend-type analysis of glaucomatous visual field defects is now easier to perform 
than it used to be, and is useful in evaluating and identifying the progression of glaucoma. It 
can detect local progression of glaucomatous visual field defects with a higher sensitivity 
than analysis of the whole field. It may be particularly suitable for the eyes with slow or 
local progression and for further elucidating the disease course in open-angle glaucoma. It 
should be considered an important method in the clinical practice setting for predicting 
QOL and QOV and for establishing treatment plans for glaucomatous patients.  
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